



VRL/SEC/EXCHANGE

13.04.2021

National Stock Exchange of India Ltd.
5th Floor, Exchange Plaza
Bandra (E),
Mumbai- 400 051

Sub.: Clarification on announcement submitted to Exchange on 13th April 2021.

Dear Sir/ Madam,

With reference to your email dated 13th April 2021 regarding clarification on press release submitted by the company, titled "Venus Remedies Enters into Partnership with West Pharmaceutical Services, Inc. to Launch Cloti-Xa (Enoxaparin Prefilled Syringes) in India with NovaGuard SA Pro Safety System.

In this regard, We wish to inform you that Cloti-Xa is a Pre-Filled Syringe of our existing product Enoxaparin and will be available in the market this month with the NovaGuard SA Pro Safety System. Further, in the initial phase, the Company intends to launch this in 10 emerging markets across the LAC, ASEAN and MENA regions.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED


(Company Secretary)
VENUS REMEDIES LIMITED

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com

www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany